Two different answers to the same hip problem

Faced with two regenerative options for hip cartilage damage, most patients ask the same practical question: are these treatments just different versions of the same idea, or do they actually work in different ways? The answer matters, because ChondroFiller™ and stem cell therapy are not interchangeable — they address the same problem through fundamentally different biological routes.

The shared problem is this: the hyaline cartilage lining the hip joint has no blood supply, which means it cannot repair itself in any meaningful way once it is damaged. Without intervention, a focal cartilage lesion tends to widen and deepen, pushing the joint progressively towards a point where total hip replacement becomes the only realistic option.

Both treatments aim to act during the preservation window — that critical period after cartilage pain begins but before end-stage arthritis closes off the conservative options. Neither is available on the NHS; both are delivered as private outpatient procedures, and neither requires a GP referral.

The distinction is in the mechanism. ChondroFiller™ is an acellular physical scaffold — no cells are introduced. Stem cell therapy introduces living progenitor cells with their own biological activity. That difference shapes everything that follows in this comparison.

What ChondroFiller™ does inside the hip joint

ChondroFiller™ is a Type I collagen hydrogel — liquid at the moment of injection, but designed to gel within minutes once inside the hip joint's warm, fluid environment. Manufactured by Meidrix Biomedicals GmbH and CE-marked as a Class III medical device, it forms a porous three-dimensional scaffold in direct contact with the damaged cartilage surface.

The mechanism is what clinicians call acellular matrix-induced chondrogenesis: the scaffold itself contains no cells, but its collagen architecture acts as a chemotactic signal, drawing the patient's own chondrocytes and progenitor cells from the surrounding synovium and subchondral bone into the repair zone. A 2025 ex vivo human osteochondral study measured a 2.4-fold increase in DNA content within the scaffold by day 14 — laboratory-level evidence that the body's own cells actively colonise the matrix. ChondroFiller™ supports the body's own repair processes rather than introducing an external biological agent.

In the current service pathway at Lincolnshire Hip, treatment is delivered via an ultrasound-guided outpatient injection — a 30–45-minute clinic appointment requiring no general anaesthetic and no hospital admission.

When placed as an injection, ChondroFiller™ works as a top-down protective coat applied across the affected cartilage surface, not only within a sharply bounded focal lesion. This means clinical suitability extends beyond patients with strictly contained defects and healthy surrounding borders, covering a wider range of surface wear presentations.

Over 19,000 cases have been performed globally, with the hip evidence base growing alongside the more established knee data. UK private guide costs start at approximately £3,000 for a single-box treatment, rising to around £8,000–£9,800 for larger or more extensive defects — the treating clinic confirms precise costs at consultation.

What stem cell therapy does inside the hip joint

Stem cell therapy takes a different biological approach: rather than placing a scaffold, it introduces living cells into the hip joint to modulate the local environment and — in some cases — stimulate repair activity.

The cells used are mesenchymal stem cells (MSCs), typically harvested from the patient's own bone marrow or adipose (fat) tissue during a same-day outpatient appointment. Once collected, the sample is concentrated before being injected into the hip joint under ultrasound or fluoroscopic guidance. Because the source material is autologous — taken from the same patient — immunological rejection is not a concern.

MSCs carry two properties that make them attractive in hip cartilage disease. First, they have well-documented anti-inflammatory effects, which may help quiet the joint environment and reduce the pain and swelling associated with progressive cartilage loss. Second, they have chondrogenic potential — under the right conditions they may encourage cartilage-related repair activity, though this does not reliably translate to structural regeneration in clinical practice.

A 2025 PRISMA-ScR scoping review covering nine clinical studies found consistent short-to-mid-term pain relief — average VAS score reductions of 30–50% — alongside meaningful Harris Hip Score and WOMAC functional gains. However, radiological evidence of cartilage repair was limited and inconsistent across those studies. A 2025 case report of a 46-year-old woman who received adipose-derived MSCs illustrates the gap between biological promise and current durability: histological analysis at 18 months confirmed areas of hyaline-like cartilage, yet symptom recurrence still led to total hip arthroplasty at that same time point.

Stem cell therapy is not routinely available on the NHS; UK private costs start around £3,900. Adverse events in reviewed studies were rare and mild, typically transient joint discomfort or local swelling.

What the clinical evidence says — and where the gaps are

Placing the two evidence bases side by side reveals a picture that is encouraging in both directions — and incomplete in both directions too.

For ChondroFiller™, the hip-specific data are relatively concrete: the +33-point Harris Hip Score gain and MOCART MRI scores in the 70–87 range noted in the sections above represent both functional recovery and imaging-confirmed structural change. The 2021 cohort study supporting these figures followed 26 patients with acetabular lesions for up to five years, with 17 of 21 assessable patients achieving good or excellent results. That study also introduced an important qualification: patients with Tönnis grade 2–3 osteoarthritis did poorly with arthroscopic implantation — though the injection pathway, which applies the collagen scaffold as a surface coat rather than a plug within a focal defect, may extend the viable severity range beyond what arthroscopic studies capture.

For stem cell therapy, the headline signal from the 2025 PRISMA-ScR scoping review — pain relief in the 30–50% range, consistent functional gains on Harris Hip Score and WOMAC across nine studies — demonstrates that MSC injection meaningfully changes how patients feel. What the same review could not confirm was meaningful, consistent cartilage repair on imaging. The 2025 case report that did show histological hyaline-like cartilage at 18 months underlines the problem rather than resolving it: biological change at the tissue level did not prevent symptom recurrence or arthroplasty in that patient.

The laboratory ex vivo finding — a 2.4-fold DNA increase within the ChondroFiller™ scaffold by day 14 — offers a mechanistic explanation for cell recruitment, but is a bench result rather than a clinical outcome measure, and should be read as supporting science rather than clinical proof.

Three evidence gaps apply equally to both treatments: no randomised controlled trial has directly compared ChondroFiller™ with MSC therapy in the hip; long-term follow-up data beyond five years are limited for both; and neither treatment has been systematically studied across the full spectrum of hip OA severity. For a patient making a decision today, the honest position is that both options have a meaningful evidence base — and that evidence does not yet resolve which approach is superior for any given hip presentation.

Which treatment fits which patient

Three clinical pictures tend to shape which approach a specialist is likely to discuss first — and understanding where you broadly fit can help you arrive at a consultation with better questions.

Focal cartilage defect, structural preservation goal. A patient with an identified focal Grade III/IV lesion in the hip, relatively healthy surrounding cartilage, and a primary aim of structural support may align more naturally with ChondroFiller's scaffold mechanism. The collagen matrix provides a physical template for the body's own cells to migrate into, and the hip-specific published data — +33 Harris Hip Score, MOCART MRI scores of 70–87 — are anchored to this type of presentation.

Pain-dominant, mild-to-moderate osteoarthritis. Where the dominant complaint is pain and inflammation rather than a single identified structural lesion, and where imaging shows early-to-moderate generalised wear, stem cell therapy's anti-inflammatory and pain-modulating properties may be the more relevant biological route. The 2025 scoping review's VAS reductions of 30–50% were recorded across mild-to-moderate presentations; the evidence does not extend reliably to advanced disease.

Wider-grade OA or diffuse surface wear. When delivered as an injectable surface coat rather than a scaffold filling a contained focal defect, ChondroFiller does not carry an automatic bone-on-bone exclusion — which may make it applicable across a broader severity range than the arthroscopic studies alone suggest. Whether that reliably extends to Tönnis grade 2 and above is still being refined in the clinical data, and a specialist's imaging assessment is what determines this, not any published checklist.

For patients in any of these groups, a productive question to bring to a consultation is: given my OA grade, defect pattern, and primary goal — structural support or symptom control — which mechanism is more likely to address what matters most to me?

Getting assessed in Lincolnshire

For Lincolnshire patients, there is a concrete practical difference between these two pathways that goes beyond mechanism and evidence.

ChondroFiller™ is available locally through Professor Paul Lee at clinics in Grantham and Sleaford. No GP referral is required to book an assessment, and there is no automatic exclusion based on age or severity — Professor Lee's team will review imaging and clinical history to establish whether the injectable scaffold pathway is appropriate for your specific hip presentation.

Stem cell therapy does not currently have an identified specialist hub within Lincolnshire; patients pursuing that route would generally need to travel outside the county to access it.

Both treatments are private and self-funded. Neither is routinely available on the NHS, and neither has received a NICE technology appraisal for hip indications — a point worth clarifying before any consultation.

The most useful next step for either pathway is the same: a specialist hip assessment covering clinical examination, current imaging, and a clear picture of your cartilage defect size and OA grade. That information is what allows a clinician to say, with reasonable confidence, which approach — scaffold, cellular, or something else — is worth pursuing.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Outcomes Following Stem Cell-Based Therapies for Hip Osteoarthritis: A Scoping Review. (2025). https://doi.org/10.7759/cureus.96419 https://doi.org/10.7759/cureus.96419
2. [2] Cartilage Repair and Symptom Relief After AutologousMicrofragmented Adipose-Derived Mesenchymal Stem Cell Therapy in Hip Osteoarthritis: A Case Report with Histological Correlation. (2025). https://doi.org/10.2174/011574888X388459250915055552 https://doi.org/10.2174/011574888X388459250915055552